ANB033
ANB033 is a novel anti-CD122 antagonist that targets the shared beta subunit of the receptors for IL-15 and IL-2
Phase 1b cohort in celiac disease to initiate by Q4 2025
R&D IR event in Q4 2025
Anti-CD122 antagonist reduces pathogenic T cells and NK cells
CD122 is a shared beta subunit of the receptors for IL-15 and IL-2
CD122 antagonist mAb will potently inhibit IL-15 and IL-2 biology
CD122 antagonist mAb will potently inhibit IL-15 and IL-2 biology
Both IL-15 and IL-2 mediate:
- Proliferation and survival of T cell subsets, particularly CD8+ TEMRA, and NK cells
- Inflammatory cytokine secretion (IFNγ) during T cell activation
ANB033 reduces pathogenic T cells
- Preferentially inhibits lower affinity dimeric IL-2 receptor complex
ANB033 has targeted reduction of CD122 expressing TRM cells
- TRM cells require IL-15 for survival
- May potentially drive durable response
Hare E, et al. FOCIS 2023. June 2023
ANB033 potently targets multiple pathogenic drivers of celiac disease
IL-15 signaling antagonism
- Reduces tissue damage by IL-15-mediated accumulation and killing activity of CD122+ intra-epithelial lymphocytes (IEL)
IL-2 signaling antagonism
- Modulates other specific immune pathways active during immune response to gluten in individuals with celiac disease, including upstream CD4 T cell-derived IFNγ, IL-2 and downstream B cell-mediated antibody responses
Further information on ANB033 MoA, preclinical data, Phase 1a data, and celiac study design to be disclosed at Q4 2025 R&D event
To access scientific publications on this topic, please click here.